Lunavelle

Lunavelle is a pre-clinical stage biotechnology company focused on developing innovative therapies for women's health conditions, specifically targeting hormonal and reproductive disorders. The company's primary research centers on the development of selective estrogen receptor modulators (SERMs) and other small molecule candidates designed to address the underlying mechanisms of endometriosis, uterine fibroids, and polycystic ovary syndrome (PCOS). By leveraging advanced medicinal chemistry and deep expertise in endocrine signaling, Lunavelle aims to provide more effective and better-tolerated treatment options for millions of women suffering from chronic gynecological diseases. The company is currently advancing its lead programs through lead optimization and early safety studies to support future IND filings.